anti-HER2 mab ELISA Kit (ab237655)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 62 ng/ml - 500 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Overview
-
Product name
anti-HER2 mab ELISA Kit
See all Anti-HER2 kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15% -
Sample type
Serum, Plasma -
Assay type
Quantitative -
Sensitivity
30 ng/ml -
Range
62 ng/ml - 500 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
anti-HER2 mab ELISA Kit (ab237655) is designed to quantify/measure the antibody against HER2 mab with high specificity and sensitivity in biological matrices.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called E4386 BioSim™ anti-HER2 Mab (Human) ELISA Kit. E4386-100 is the same size as the 96 test size of ab237655.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Anti-HER2 mab Standard S1 1 x 1ml Anti-HER2 mab Standard S2 1 x 1ml Anti-HER2 mab Standard S3 1 x 1ml Anti-HER2 mab Standard S4 1 x 1ml Anti-HER2 mab Standard S5 1 x 1ml Anti-HER2 mab Standard S6 1 x 1ml Anti-HER2 mab Standard S7 1 x 1ml Assay Buffer 1 x 50ml Confirmation Reagent 1 x 12ml Micro ELISA Plate 1 unit Peroxidase Conjugate 1 x 12ml Plate sealers 2 units Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash buffer (20X) 1 x 50ml -
Relevance
This product is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). It has anti-tumor activity against HER2-positive human breast tumor cells in laboratory models and is active for the treatment of women with HER2-overexpressing breast cancers. This antibody was approved in 1998 for clinical use for HER2 overexpressing metastatic breast cancer. In HER2 overexpressing cells, it markedly down-regulates HER2 expression by accelerating receptor endocytosis and degradation and inhibits cell cycle progression by inducing the formation of p27Kip1/Cdk2 complexes. -
Alternative names
- human epidermal growth factor receptor 2
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab237655 has not yet been referenced specifically in any publications.